NCT01229332View on ClinicalTrials.gov

A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Parkinson's Disease
Interventions
DRUG

Saline

Continuous 24 h administration

DRUG

Carbidopa

Continuous 24 h administration

Trial Locations (1)

Unknown

Hadassah Medical Center, Jerusalem

Sponsors

Lead Sponsor

NeuroDerm Ltd.
All Listed Sponsors
lead

NeuroDerm Ltd.

INDUSTRY

NCT01229332 - A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients | Biotech Hunter | Biotech Hunter